The global Dengue Vaccines market size was valued at USD 412.2 million in 2022 and is forecast to a readjusted size of USD 1010.9 million by 2029 with a CAGR of 13.7% during review period.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected. The value of the vaccine is limited by the fact that it may worsen outcomes in those who have not previously been infected. It is given as three injections over a year.
The only one version which is commercially available now, known as Dengvaxia and produced by Sanofi, don't have enough efficacy. While there are several vaccines are on trial now. TAK-003, developed by Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a massive Phase III trial.
This report is a detailed and comprehensive analysis for global Dengue Vaccines market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Dengue Vaccines market size and forecasts, in consumption value ($ Million), 2018-2029
Global Dengue Vaccines market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Dengue Vaccines market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Dengue Vaccines market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Dengue Vaccines
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Dengue Vaccines market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Sanofi
Takeda
Dengvaxia
TAK-003
Others
Public Sector
Private Sector
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Strengths:
- Rising awareness and global initiatives for dengue prevention are increasing the demand for vaccines.
- Technological advancements in vaccine development have led to more effective and safe dengue vaccines.
Weaknesses:
- High cost of dengue vaccine production limits widespread adoption, especially in low-income regions.
- Vaccine efficacy may vary based on different serotypes of the dengue virus, complicating market penetration.
Opportunities:
- Expanding government and international funding for dengue control initiatives could boost market growth.
- Emerging markets in Southeast Asia and Latin America present significant growth potential due to the high prevalence of dengue.
Threats:
- The emergence of new dengue virus strains may reduce the effectiveness of existing vaccines.
- Regulatory hurdles and approval delays in key markets could slow down vaccine availability.
Political:
- Government policies and funding in endemic countries drive the adoption and distribution of dengue vaccines.
- International cooperation between governments and health organizations is crucial for addressing global dengue outbreaks.
Economic:
- High vaccine production and distribution costs could hinder market growth, particularly in developing countries.
- Economic growth in emerging markets, especially in Southeast Asia, may increase demand for vaccines.
Social:
- Growing public awareness about the importance of vaccination and disease prevention can drive vaccine uptake.
- Cultural and regional differences in vaccine acceptance may impact the speed of market penetration in certain areas.
Technological:
- Advancements in biotechnology and vaccine development are improving vaccine efficacy and safety profiles.
- Digital platforms and mobile health technologies can aid in vaccine education, distribution, and monitoring.
Environmental:
- Climate change may affect the spread of dengue, increasing the demand for vaccines in new regions.
- Sustainable vaccine production methods are needed to reduce environmental impacts of large-scale manufacturing.
Legal:
- Regulatory approval processes for new dengue vaccines can be lengthy and vary by region, affecting market entry.
- Patent laws and intellectual property rights can influence competition and accessibility in the dengue vaccine market.
Suppliers:
- Pharmaceutical companies and biotech firms developing and manufacturing dengue vaccines.
- Research institutions and universities conducting clinical trials and studies to support vaccine efficacy.
Inputs:
- Raw materials for vaccine production, such as viral strains and adjuvants.
- Regulatory approvals, clinical data, and funding for vaccine development.
Process:
- Vaccine development, including research, trials, and manufacturing.
- Distribution and supply chain management for global delivery, particularly in endemic regions.
Outputs:
- Dengue vaccines that are safe, effective, and ready for public use.
- Vaccination programs and initiatives that promote public health in endemic areas.
Customers:
- Government health organizations and international health bodies procuring vaccines for mass vaccination campaigns.
- End-users such as healthcare providers, hospitals, and individuals in high-risk dengue regions.
Threat of New Entrants:
- High research and development costs, along with regulatory hurdles, create significant barriers to entry for new players.
- Established vaccine manufacturers with expertise and distribution networks hold a competitive advantage, limiting opportunities for new entrants.
Bargaining Power of Suppliers:
- Limited suppliers of specialized raw materials and vaccine components (e.g., viral strains, adjuvants) give suppliers higher bargaining power.
- Vaccine manufacturing requires specialized knowledge and technology, so suppliers of these technologies also hold considerable power.
Bargaining Power of Buyers:
- Governments and large health organizations, as major buyers, have significant negotiating power to secure lower prices or better terms.
- In regions with widespread dengue outbreaks, the demand for vaccines may outweigh buyers' bargaining power, limiting their influence.
Threat of Substitutes:
- Lack of direct substitutes for vaccines makes the threat of alternatives low in preventing dengue.
- However, other public health measures, such as vector control and public awareness campaigns, may be viewed as supplementary approaches to vaccination.
Industry Rivalry:
- Intense competition among established pharmaceutical companies to develop the most effective and safe dengue vaccines.
- High competition in terms of pricing, distribution agreements, and market share in endemic regions increases industry rivalry.
Raw Materials & Components:
- High-quality viral strains, adjuvants, and excipients are essential inputs for developing dengue vaccines, with limited suppliers controlling key components.
- The cost and availability of specialized materials, including bioreactors and cell culture systems, impact vaccine production timelines and pricing.
Research & Development:
- Significant investments in R&D by pharmaceutical companies and academic institutions are driving innovation and the development of next-generation dengue vaccines.
- Collaborations between public and private sectors for clinical trials and data sharing are critical to advancing vaccine efficacy and approval.
Regulatory & Compliance:
- Vaccine developers face strict regulatory requirements for safety and efficacy, particularly in endemic regions, which can delay product development.
- Compliance with international standards (e.g., WHO, FDA) is crucial for market access and widespread adoption of dengue vaccines.
Technology & Innovation:
- Advancements in biotechnology, including mRNA technology and vector-based vaccines, are enabling faster and more effective dengue vaccine development.
- The need for scalable production technologies that can meet global vaccine demand is driving innovation in manufacturing processes.
Manufacturing & Production:
- Advanced biomanufacturing capabilities and large-scale production facilities are essential to meet the growing demand for dengue vaccines in endemic regions.
- The complexity of vaccine formulation, quality control, and regulatory compliance makes manufacturing processes critical to market success.
Distribution & Supply Chain:
- Efficient global distribution networks, particularly in high-risk dengue areas, are key to ensuring timely vaccine delivery and coverage.
- Cold chain logistics and proper storage conditions are crucial to maintaining vaccine efficacy, especially in tropical climates where dengue is prevalent.
Marketing & Sales:
- Strong partnerships with government agencies, health organizations, and NGOs are vital for securing vaccine contracts and ensuring market penetration.
- Effective marketing strategies, including public health campaigns and education on vaccine safety and efficacy, can drive demand in endemic regions.
Healthcare Providers & Distribution:
- Hospitals, clinics, and local healthcare providers play a critical role in administering dengue vaccines to the at-risk population, ensuring coverage in endemic regions.
- Mobile vaccination units and community-based healthcare outreach programs are essential for reaching remote and underserved populations.
End-Users & Demand:
- Governments and international health organizations, as major buyers, drive demand for dengue vaccines through national immunization programs.
- Public awareness and vaccine acceptance are key factors influencing demand, especially in regions with high levels of vaccine hesitancy.
Chapter 1, to describe Dengue Vaccines product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Dengue Vaccines, with revenue, gross margin and global market share of Dengue Vaccines from 2018 to 2023.
Chapter 3, the Dengue Vaccines competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Dengue Vaccines market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Dengue Vaccines.
Chapter 13, to describe Dengue Vaccines research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Dengue Vaccines
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Dengue Vaccines by Type
1.3.1 Overview: Global Dengue Vaccines Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Dengue Vaccines Consumption Value Market Share by Type in 2022
1.3.3 Dengvaxia
1.3.4 TAK-003
1.3.5 Others
1.4 Global Dengue Vaccines Market by Application
1.4.1 Overview: Global Dengue Vaccines Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Public Sector
1.4.3 Private Sector
1.5 Global Dengue Vaccines Market Size & Forecast
1.6 Global Dengue Vaccines Market Size and Forecast by Region
1.6.1 Global Dengue Vaccines Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Dengue Vaccines Market Size by Region, (2018-2029)
1.6.3 North America Dengue Vaccines Market Size and Prospect (2018-2029)
1.6.4 Europe Dengue Vaccines Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Dengue Vaccines Market Size and Prospect (2018-2029)
1.6.6 South America Dengue Vaccines Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Dengue Vaccines Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Dengue Vaccines Product and Solutions
2.1.4 Sanofi Dengue Vaccines Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Dengue Vaccines Product and Solutions
2.2.4 Takeda Dengue Vaccines Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Takeda Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Dengue Vaccines Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Dengue Vaccines by Company Revenue
3.2.2 Top 3 Dengue Vaccines Players Market Share in 2022
3.2.3 Top 6 Dengue Vaccines Players Market Share in 2022
3.3 Dengue Vaccines Market: Overall Company Footprint Analysis
3.3.1 Dengue Vaccines Market: Region Footprint
3.3.2 Dengue Vaccines Market: Company Product Type Footprint
3.3.3 Dengue Vaccines Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Dengue Vaccines Consumption Value and Market Share by Type (2018-2023)
4.2 Global Dengue Vaccines Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Dengue Vaccines Consumption Value Market Share by Application (2018-2023)
5.2 Global Dengue Vaccines Market Forecast by Application (2024-2029)
6 North America
6.1 North America Dengue Vaccines Consumption Value by Type (2018-2029)
6.2 North America Dengue Vaccines Consumption Value by Application (2018-2029)
6.3 North America Dengue Vaccines Market Size by Country
6.3.1 North America Dengue Vaccines Consumption Value by Country (2018-2029)
6.3.2 United States Dengue Vaccines Market Size and Forecast (2018-2029)
6.3.3 Canada Dengue Vaccines Market Size and Forecast (2018-2029)
6.3.4 Mexico Dengue Vaccines Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Dengue Vaccines Consumption Value by Type (2018-2029)
7.2 Europe Dengue Vaccines Consumption Value by Application (2018-2029)
7.3 Europe Dengue Vaccines Market Size by Country
7.3.1 Europe Dengue Vaccines Consumption Value by Country (2018-2029)
7.3.2 Germany Dengue Vaccines Market Size and Forecast (2018-2029)
7.3.3 France Dengue Vaccines Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Dengue Vaccines Market Size and Forecast (2018-2029)
7.3.5 Russia Dengue Vaccines Market Size and Forecast (2018-2029)
7.3.6 Italy Dengue Vaccines Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Dengue Vaccines Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Dengue Vaccines Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Dengue Vaccines Market Size by Region
8.3.1 Asia-Pacific Dengue Vaccines Consumption Value by Region (2018-2029)
8.3.2 China Dengue Vaccines Market Size and Forecast (2018-2029)
8.3.3 Japan Dengue Vaccines Market Size and Forecast (2018-2029)
8.3.4 South Korea Dengue Vaccines Market Size and Forecast (2018-2029)
8.3.5 India Dengue Vaccines Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Dengue Vaccines Market Size and Forecast (2018-2029)
8.3.7 Australia Dengue Vaccines Market Size and Forecast (2018-2029)
9 South America
9.1 South America Dengue Vaccines Consumption Value by Type (2018-2029)
9.2 South America Dengue Vaccines Consumption Value by Application (2018-2029)
9.3 South America Dengue Vaccines Market Size by Country
9.3.1 South America Dengue Vaccines Consumption Value by Country (2018-2029)
9.3.2 Brazil Dengue Vaccines Market Size and Forecast (2018-2029)
9.3.3 Argentina Dengue Vaccines Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Dengue Vaccines Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Dengue Vaccines Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Dengue Vaccines Market Size by Country
10.3.1 Middle East & Africa Dengue Vaccines Consumption Value by Country (2018-2029)
10.3.2 Turkey Dengue Vaccines Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Dengue Vaccines Market Size and Forecast (2018-2029)
10.3.4 UAE Dengue Vaccines Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Dengue Vaccines Market Drivers
11.2 Dengue Vaccines Market Restraints
11.3 Dengue Vaccines Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Dengue Vaccines Industry Chain
12.2 Dengue Vaccines Upstream Analysis
12.3 Dengue Vaccines Midstream Analysis
12.4 Dengue Vaccines Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Dengue Vaccines Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Dengue Vaccines Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Dengue Vaccines Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Dengue Vaccines Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Dengue Vaccines Product and Solutions
Table 8. Sanofi Dengue Vaccines Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Takeda Company Information, Head Office, and Major Competitors
Table 11. Takeda Major Business
Table 12. Takeda Dengue Vaccines Product and Solutions
Table 13. Takeda Dengue Vaccines Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Takeda Recent Developments and Future Plans
Table 15. Global Dengue Vaccines Revenue (USD Million) by Players (2018-2023)
Table 16. Global Dengue Vaccines Revenue Share by Players (2018-2023)
Table 17. Breakdown of Dengue Vaccines by Company Type (Tier 1, Tier 2, and Tier 3)
Table 18. Market Position of Players in Dengue Vaccines, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 19. Head Office of Key Dengue Vaccines Players
Table 20. Dengue Vaccines Market: Company Product Type Footprint
Table 21. Dengue Vaccines Market: Company Product Application Footprint
Table 22. Dengue Vaccines New Market Entrants and Barriers to Market Entry
Table 23. Dengue Vaccines Mergers, Acquisition, Agreements, and Collaborations
Table 24. Global Dengue Vaccines Consumption Value (USD Million) by Type (2018-2023)
Table 25. Global Dengue Vaccines Consumption Value Share by Type (2018-2023)
Table 26. Global Dengue Vaccines Consumption Value Forecast by Type (2024-2029)
Table 27. Global Dengue Vaccines Consumption Value by Application (2018-2023)
Table 28. Global Dengue Vaccines Consumption Value Forecast by Application (2024-2029)
Table 29. North America Dengue Vaccines Consumption Value by Type (2018-2023) & (USD Million)
Table 30. North America Dengue Vaccines Consumption Value by Type (2024-2029) & (USD Million)
Table 31. North America Dengue Vaccines Consumption Value by Application (2018-2023) & (USD Million)
Table 32. North America Dengue Vaccines Consumption Value by Application (2024-2029) & (USD Million)
Table 33. North America Dengue Vaccines Consumption Value by Country (2018-2023) & (USD Million)
Table 34. North America Dengue Vaccines Consumption Value by Country (2024-2029) & (USD Million)
Table 35. Europe Dengue Vaccines Consumption Value by Type (2018-2023) & (USD Million)
Table 36. Europe Dengue Vaccines Consumption Value by Type (2024-2029) & (USD Million)
Table 37. Europe Dengue Vaccines Consumption Value by Application (2018-2023) & (USD Million)
Table 38. Europe Dengue Vaccines Consumption Value by Application (2024-2029) & (USD Million)
Table 39. Europe Dengue Vaccines Consumption Value by Country (2018-2023) & (USD Million)
Table 40. Europe Dengue Vaccines Consumption Value by Country (2024-2029) & (USD Million)
Table 41. Asia-Pacific Dengue Vaccines Consumption Value by Type (2018-2023) & (USD Million)
Table 42. Asia-Pacific Dengue Vaccines Consumption Value by Type (2024-2029) & (USD Million)
Table 43. Asia-Pacific Dengue Vaccines Consumption Value by Application (2018-2023) & (USD Million)
Table 44. Asia-Pacific Dengue Vaccines Consumption Value by Application (2024-2029) & (USD Million)
Table 45. Asia-Pacific Dengue Vaccines Consumption Value by Region (2018-2023) & (USD Million)
Table 46. Asia-Pacific Dengue Vaccines Consumption Value by Region (2024-2029) & (USD Million)
Table 47. South America Dengue Vaccines Consumption Value by Type (2018-2023) & (USD Million)
Table 48. South America Dengue Vaccines Consumption Value by Type (2024-2029) & (USD Million)
Table 49. South America Dengue Vaccines Consumption Value by Application (2018-2023) & (USD Million)
Table 50. South America Dengue Vaccines Consumption Value by Application (2024-2029) & (USD Million)
Table 51. South America Dengue Vaccines Consumption Value by Country (2018-2023) & (USD Million)
Table 52. South America Dengue Vaccines Consumption Value by Country (2024-2029) & (USD Million)
Table 53. Middle East & Africa Dengue Vaccines Consumption Value by Type (2018-2023) & (USD Million)
Table 54. Middle East & Africa Dengue Vaccines Consumption Value by Type (2024-2029) & (USD Million)
Table 55. Middle East & Africa Dengue Vaccines Consumption Value by Application (2018-2023) & (USD Million)
Table 56. Middle East & Africa Dengue Vaccines Consumption Value by Application (2024-2029) & (USD Million)
Table 57. Middle East & Africa Dengue Vaccines Consumption Value by Country (2018-2023) & (USD Million)
Table 58. Middle East & Africa Dengue Vaccines Consumption Value by Country (2024-2029) & (USD Million)
Table 59. Dengue Vaccines Raw Material
Table 60. Key Suppliers of Dengue Vaccines Raw Materials
List of Figures
Figure 1. Dengue Vaccines Picture
Figure 2. Global Dengue Vaccines Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Dengue Vaccines Consumption Value Market Share by Type in 2022
Figure 4. Dengvaxia
Figure 5. TAK-003
Figure 6. Others
Figure 7. Global Dengue Vaccines Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Dengue Vaccines Consumption Value Market Share by Application in 2022
Figure 9. Public Sector Picture
Figure 10. Private Sector Picture
Figure 11. Global Dengue Vaccines Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Dengue Vaccines Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Dengue Vaccines Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Dengue Vaccines Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Dengue Vaccines Consumption Value Market Share by Region in 2022
Figure 16. North America Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Dengue Vaccines Revenue Share by Players in 2022
Figure 22. Dengue Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Dengue Vaccines Market Share in 2022
Figure 24. Global Top 6 Players Dengue Vaccines Market Share in 2022
Figure 25. Global Dengue Vaccines Consumption Value Share by Type (2018-2023)
Figure 26. Global Dengue Vaccines Market Share Forecast by Type (2024-2029)
Figure 27. Global Dengue Vaccines Consumption Value Share by Application (2018-2023)
Figure 28. Global Dengue Vaccines Market Share Forecast by Application (2024-2029)
Figure 29. North America Dengue Vaccines Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Dengue Vaccines Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Dengue Vaccines Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Dengue Vaccines Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Dengue Vaccines Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Dengue Vaccines Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 39. France Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Dengue Vaccines Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Dengue Vaccines Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Dengue Vaccines Consumption Value Market Share by Region (2018-2029)
Figure 46. China Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 49. India Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Dengue Vaccines Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Dengue Vaccines Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Dengue Vaccines Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Dengue Vaccines Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Dengue Vaccines Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Dengue Vaccines Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Dengue Vaccines Consumption Value (2018-2029) & (USD Million)
Figure 63. Dengue Vaccines Market Drivers
Figure 64. Dengue Vaccines Market Restraints
Figure 65. Dengue Vaccines Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Dengue Vaccines in 2022
Figure 68. Manufacturing Process Analysis of Dengue Vaccines
Figure 69. Dengue Vaccines Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
